TherapeuticsMD Cash Flow - Quarterly (NASDAQ:TXMD)

Add to My Stocks
$6.14 $0.14 (2.23%) TXMD stock closing price Sep 17, 2018 (Closing)

The TherapeuticsMD cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows TherapeuticsMD profits, the balance sheet shows TherapeuticsMD debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. TherapeuticsMD stock analysis shows negative net income cash flow of $-57.62M till 2018 Q2. This statement is important because profits alone cannot pay employees, or bills. Cash is required. The cash from operating activities for TherapeuticsMD is $ 2018 Q2, which saw a decrease from previous quarter.

View and download details of TherapeuticsMD cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities8.7M2.91M-6.33M-5.04M-0.96M-0.83M--2.21M-2.39M-3.11M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.17M1.77M6.89M5.03M3.03M1.41M19.93M15.64M9.64M4.61M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.05M-0.02M-0.06M-0.03M-0.03M-0.02M-0.39M-0.3M-0.26M-0.07M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities-0.45M-0.15M-0.76M-0.43M-0.36M-0.1M-0.85M-0.55M-0.39M-0.09M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares1.13M-72.58M72.58M4.01M2.65M137.22M137.21M137.21M136.95M
Issuance (Repayment) of Debt Securities75M---------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-3.79M---------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year127.14M131.53M64.7M51.36M54.19M1.55M----
Cash & Equivalents at Year End154.39M107.34M127.13M148.29M96.47M113.52M131.53M147.53M166.53M182.09M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The TherapeuticsMD stock price history and TherapeuticsMD stock comparison chart inevitably reflect its cash flow situation.

  • TherapeuticsMD had a Net Change in Cash and Cash Equivalents of $27.25M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the TherapeuticsMD stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-44.6M for TXMD.
  • Cash Flow from investment activities: TherapeuticsMD used $-0.49M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $72.34M for TherapeuticsMD.

Key Financial Ratios For TherapeuticsMD Cash Flow

Quarterly Cash Flow Statements For TherapeuticsMD Inc Peers

Juniper Pharma cash flow, Novo Nordisk cash flow, Pfizer cash flow, Theravance Biopharma cash flow